Viracta Therapeutics, Inc. (VIRX)
USD 0.02
(14.44%)
USD 0.02
(14.44%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.32 USD | 0.0% |
| 2022 | -1.32 USD | 79.28% |
| 2021 | -6.37 USD | 96.92% |
| 2020 | -206.93 USD | -2108.43% |
| 2019 | -9.37 USD | 64.21% |
| 2018 | -26.18 USD | 48.28% |
| 2017 | -50.62 USD | 40.33% |
| 2016 | -84.83 USD | 19.67% |
| 2015 | -105.60 USD | -136.35% |
| 2014 | -44.68 USD | -3.71% |
| 2013 | -43.08 USD | 24.53% |
| 2012 | -57.08 USD | -115.97% |
| 2011 | -26.43 USD | 55.46% |
| 2010 | -59.34 USD | 91.04% |
| 2009 | -662.05 USD | -69.28% |
| 2008 | -391.09 USD | 12.86% |
| 2007 | -448.80 USD | -10.81% |
| 2006 | -405.03 USD | 5.99% |
| 2005 | -430.85 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.23 USD | 34.29% |
| 2024 Q2 | -0.25 USD | -8.7% |
| 2023 Q3 | -0.33 USD | -3.13% |
| 2023 Q1 | -0.34 USD | -25.93% |
| 2023 Q2 | -0.32 USD | 5.88% |
| 2023 FY | - USD | 0.0% |
| 2023 Q4 | -0.35 USD | -6.06% |
| 2022 Q2 | -0.28 USD | 0.0% |
| 2022 FY | - USD | 79.28% |
| 2022 Q1 | -0.28 USD | 9.68% |
| 2022 Q4 | -0.27 USD | 41.3% |
| 2022 Q3 | -0.46 USD | -64.29% |
| 2021 Q2 | -0.25 USD | 95.21% |
| 2021 Q1 | -5.22 USD | -1173.17% |
| 2021 Q4 | -0.31 USD | 22.5% |
| 2021 Q3 | -0.40 USD | -60.0% |
| 2021 FY | - USD | 96.92% |
| 2020 Q4 | -0.41 USD | -272.73% |
| 2020 Q1 | -0.12 USD | 75.0% |
| 2020 FY | - USD | -2108.43% |
| 2020 Q2 | -0.11 USD | 8.33% |
| 2020 Q3 | -0.11 USD | 0.0% |
| 2019 Q2 | -0.88 USD | 14.56% |
| 2019 Q3 | -0.57 USD | 35.23% |
| 2019 Q4 | -0.48 USD | 15.79% |
| 2019 FY | - USD | 64.21% |
| 2019 Q1 | -1.03 USD | 38.69% |
| 2018 Q3 | -1.88 USD | 9.18% |
| 2018 FY | - USD | 48.28% |
| 2018 Q2 | -2.07 USD | 5.91% |
| 2018 Q1 | -2.20 USD | -0.92% |
| 2018 Q4 | -1.68 USD | 10.64% |
| 2017 Q4 | -2.18 USD | 50.57% |
| 2017 Q3 | -4.41 USD | -3.28% |
| 2017 FY | - USD | 40.33% |
| 2017 Q2 | -4.27 USD | 13.03% |
| 2017 Q1 | -4.91 USD | -5.14% |
| 2016 Q4 | -4.67 USD | 28.15% |
| 2016 Q3 | -6.50 USD | 13.79% |
| 2016 FY | - USD | 19.67% |
| 2016 Q2 | -7.54 USD | -4.87% |
| 2016 Q1 | -7.19 USD | 22.19% |
| 2015 FY | - USD | -136.35% |
| 2015 Q3 | -5.82 USD | 23.42% |
| 2015 Q4 | -9.24 USD | -58.76% |
| 2015 Q2 | -7.60 USD | 8.54% |
| 2015 Q1 | -8.31 USD | -432.69% |
| 2014 Q2 | -12.20 USD | 24.27% |
| 2014 FY | - USD | -3.71% |
| 2014 Q1 | -16.11 USD | -93.86% |
| 2014 Q4 | -1.56 USD | 89.98% |
| 2014 Q3 | -15.57 USD | -27.62% |
| 2013 Q4 | -8.31 USD | 13.8% |
| 2013 Q3 | -9.64 USD | 7.4% |
| 2013 FY | - USD | 24.53% |
| 2013 Q2 | -10.41 USD | 28.16% |
| 2013 Q1 | -14.49 USD | -1641.49% |
| 2012 Q3 | -32.23 USD | -211.7% |
| 2012 FY | - USD | -115.97% |
| 2012 Q4 | 0.94 USD | 102.92% |
| 2012 Q1 | -23.98 USD | -113.92% |
| 2012 Q2 | -10.34 USD | 56.88% |
| 2011 Q3 | -6.44 USD | 39.59% |
| 2011 Q1 | 2.41 USD | 118.3% |
| 2011 Q2 | -10.66 USD | -542.32% |
| 2011 FY | - USD | 55.46% |
| 2011 Q4 | -11.21 USD | -74.07% |
| 2010 Q2 | -26.30 USD | 32.63% |
| 2010 FY | - USD | 91.04% |
| 2010 Q4 | -13.17 USD | -59.64% |
| 2010 Q3 | -8.25 USD | 68.63% |
| 2010 Q1 | -39.04 USD | -15.03% |
| 2009 FY | - USD | -69.28% |
| 2009 Q3 | -51.76 USD | 78.37% |
| 2009 Q2 | -239.30 USD | -121.12% |
| 2009 Q1 | -108.22 USD | -49.33% |
| 2009 Q4 | -33.94 USD | 34.43% |
| 2008 Q1 | -100.83 USD | -9.65% |
| 2008 Q3 | -73.93 USD | 47.97% |
| 2008 Q4 | -72.47 USD | 1.97% |
| 2008 Q2 | -142.09 USD | -40.92% |
| 2008 FY | - USD | 12.86% |
| 2007 Q3 | -113.74 USD | -0.8% |
| 2007 Q2 | -112.84 USD | 1.45% |
| 2007 Q1 | -114.50 USD | -3.75% |
| 2007 Q4 | -91.96 USD | 19.15% |
| 2007 FY | - USD | -10.81% |
| 2006 Q2 | -55.32 USD | 60.69% |
| 2006 Q4 | -110.36 USD | -2.97% |
| 2006 FY | - USD | 5.99% |
| 2006 Q1 | -140.71 USD | -68.92% |
| 2006 Q3 | -107.18 USD | -93.75% |
| 2005 Q3 | -88.43 Thousand USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | -83.30 USD | 99.91% |